INTRODUCTION
According to World Health Organization reports on 2010, 9 million new and relapse tuberculosis (TB) cases has been estimated around the world and 17,000 patients with TB in Iran. [1] Due to the prevalence of TB in our area, detection of latent tuberculosis infection (LTBI) in limited groups of patients such as a candidate for organ transplants or other immunosuppressed individuals is very important and useful. The incidence of LTBI among kidney transplant recipients is estimated at 20-70 times higher than in the general population. [2] Therefore, current guidelines recommend a generalized screening for evidence of latent infection prior to and a er transplantation, to start target appropriate preventative prophylaxis. [3] The tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are standard immunologic tools for LTBI detection. [4] Until 2001, the TST was the only method and gold standard for diagnosing LTBI, [5] but a er that developing IGRAs change the way. These tests measure .TB test positivity. Although isoniazid prophylaxis was used for patients with positive TST and/or T-SPOT to the high prevalence of TB would be able to prevent active TB. The currently recommended prophylaxis of latent TB in our country is based on the monotherapy with isoniazid (isonicotinylhydrazine) for at least 9 months. [11] Therefore, in this study the patients with positive tests, received isoniazid prophylaxis and had been followed up for active TB for 1 year.
MATERIALS AND METHODS

Patient population and study design
This prospective study was conducted in the teaching hospitals of Isfahan University of Medical Sciences, Iran, from March 2010 to February 2011 and was approved by the Ethics Commi ee of this University (Research project number: 185185). A total of 44 adult patients candidate for receiving a kidney transplant were included in the study. These patients were evaluated for ruling out active pulmonary and extra-pulmonary TB. Individuals with a history of prior TB or isoniazid prophylactic treatment were excluded. Furthermore, if patients refused to continue prophylactic treatment and following up and/or symptoms of isoniazid-induced hepatitis or drug reaction were occurred, they were excluded. Demographic and clinical details were obtained from each patient by a detailed questionnaire. Patients underwent TST and T-SPOT ® .TB testing before scheduled transplant surgery (blood samples were collected before TST) and follow up for activating LTBI a er surgery.
T-SPOT
® .TB testing T-SPOT ® .TB assay (Oxford Immunotec, Oxford, UK) was performed according to the manufacturers' recommendation and defi ned as positive, negative or indeterminate based on manufacturers' recommended criteria. Briefl y, before the TST, 8 ml peripheral venous blood was collected and processed within 4 h. The peripheral blood mononuclear cells (PBMCs) were isolated by standard fi coll-hypaque density-gradient centrifugation. The PBMCs were counted and adjusted to a cell number of 2. , the nil control well contained the cell in medium alone, and the positive control well contained the cell that was stimulated with phytohemagglutinin. A er the appropriate incubation time (16-20 h) at in a humidifi ed incubator at 37°C and 5% CO 2 , the plates were washed with phosphate-buff ered saline (PBS) four times. An appropriate volume of conjugate working solution was prepared (1:200 dilution in PBS) for the secondary incubation (60 min at 2-8°C) a er which the wells was washed again (×4), as suggested above. Results are presented as the number of spot-forming cells and the reaction was observed visually. We used criteria for positive, negative, and indeterminate outcomes that were recommended by the manufacturer.
TST TST was performed using the 5 IU purified protein derivative (PPD) (Pasteur Institute, Tehran, Iran) injection into the volar aspect of the forearm intradermally by trained personnel. A positive test was defi ned by the size of induration (not the erythema) induced by PPD 48-72 h a er the injection. If induration size was ≥10 mm, test was considered positive as recommended by local guidelines (Ministry of Health and Medical Education). [11] Patients follow up for activating LTBI For all individuals with a positive skin test and/or T-SPOT ® . TB test isoniazid prophylaxis was started and continued for 9 months, according to national guidelines and recent studies. [11] [12] [13] A er transplantation, patients were followed up for 1 year. If suspected sign and symptoms of TB were observed in these patients, they were evaluated for pulmonary and extra-pulmonary TB based on symptoms by specialists.
Statistical analysis
The results were analyzed using the SPSS so ware, All tests of signifi cance were two-tailed; P ≤ 0.05 were considered to be signifi cant.
RESULTS
A total of 44 adult patients that candidate for receiving kidney transplant were enrolled in the study. Demographic and clinical characteristics of patients are shown in [ .TB test and TST was 86%. The induration size on TST was signifi cantly associated with positivity on the T-SPOT ® .TB test [P < 0.001, Figure 1] . None of the patients had recent contact with active TB case. The relation between history of BCG vaccination and underlying diseases and two tests are shown in [ Table 3 ]. We found that 10 (22.7%) patients had positive skin test and/or T-SPOT ® .TB test and they had indication to start isoniazid prophylaxis. Of these, four had positive results for two tests, four had positive TST, but negative T-SPOT ® .TB test and two had negative TST but positive T-SPOT ® .TB test. Although, all the patients with positive test had isoniazid prophylaxis, one patient was diagnosed as active TB a er tuberculin prophylaxis. This patient has positive results in both tests. In addition, one patient with TST positive result was lost to follow-up a er transplantation, because of his death that was caused by renal transplant rejection.
DISCUSSION
Although IGRAs are increasingly recommended for diagnosis of TB, [14] but in our region IGRAs has been used in research se ings only, and these tests are not routine. The renal transplant recipients are usually screened for LTBI by TST. In this study, the usefulness of TST and T-SPOT ® .TB test to detect LTBI was tested in renal transplant candidates. In our study, 18.2% of renal transplant candidates were TST positive and 13.6% were T-SPOT ® .TB test positive. Ahmadinejad et al. used TST and QuantiFERON ® -TB (QFT) Gold for detection of LTBI in candidates of kidney transplantation. They found that 21.9% patients had positive TST and QFT Gold and agreement between QFT and TST was 75%. Furthermore, they did not fi nd any association between two test and BCG vaccination. [10] In another study by Kim et al., 22% and 30% renal recipients had positive TST and T-SPOT ® .TB test; respectively. They reported the agreement between two tests was fair. [9] In other studies, the diff erent percentages of TST and IGRAs positivity were reported in immunosuppressed and hemodialysis patients. Seyhan et al. have reported 34% and 43% TST and QFT Gold positivity in hemodialysis patients; respectively, and agreement between two test was 65%. [15] Also Soysal et al. reported 39% and 61% TST and T-SPOT ® .TB test positivity in this group of patients; respectively and agreement between two test was 60%. [16] Piana et al. found 17.4% and 44.2% TST and T-SPOT ® .TB test positivity in immunosuppressed hematology patients; respectively and agreement between two tests was 67.8%. [17] The positive percentage of our results are less than other studies and agreement between two tests was moderate, although the induration size of TST signifi cantly associated with positivity on T-SPOT ® .TB test. Due to lack of access to complete clinical records of transplant recipient candidates and the absence of organ transplantation bank in our country, the patients may be immuncompormised before the assays because of their underlying disease or their treatment schedule. These reasons can be caused the T-SPOT ® .TB test false negative results in our study. There are few studies on isoniazid prophylaxis in transplant candidates. In our study, 10 patients had indication for isoniazid prophylaxis. None of them had previously received anti-TB drugs. Kim et al. found that 27 patients had indication for isoniazid prophylaxis and of these, only fi ve patients received isoniazid. They did not mention how long patients were followed up and whether the isoniazid prophylaxis is eff ective or not. [9] In our study, a er the prophylaxis, one patient was diagnosed with active TB. These fi ndings show that isoniazid prophylaxis was not as eff ective as we thought and we should use a more eff ective regimen. Also, there is few data on the appropriate time to begin the prophylactic treatment. Some patients require immediate transplantation and they receive immunosuppressive drug before the prophylaxis is completed. Thus, additional studies are needed to determine the right time to begin the prophylaxis.
CONCLUSION
Because there is no diagnostic gold standard test for LTBI, the evaluation of sensitivity and specifi city of IGRAs is diffi cult. Therefore, further studies are needed in various patients with diff erent levels of the competency of the immune system. In addition, these tests should be evaluated in diff erent geographic areas according to the incidence of TB, performance of BCG vaccination and the social and health level.
